Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%1), Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets

Alfasigma S.p.A (“Alfasigma” or the “Company”), a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered, today announced its financial results for the fiscal year 2025. Its results reflect a year of strategic evolution and solid performance of key brands – all contributing to market share growth. Despite its voluntary withdrawal of Ocaliva® from the US market, Alfasigma delivered strong performance through its disciplined investment strategy and effective execution, unlocking opportunities and building momentum across its key therapeutic areas (gastroenterology, vascular & immunology) and consumer healthcare.

Growing Performance Across Products and Markets

Alfasigma saw double-digit growth from many of its brands namely Vessel®, Normix® and Jyseleca® and the Esoxx (reflux) brand family. Similarly, Alfasigma saw significant growth across its Growth Markets (+15% vs PY) and Western Europe (+11%¹ vs PY) segments, from investments in expanded commercial teams, targeted media spend, and new affiliates leading to the increase in market share. Over 2025, the Company added new locations (KSA and Hungary) bringing its products to more patients worldwide.

Continued investments to expand Innovative Portfolio

Investment partnerships were announced following the reporting period, including the March 2026 agreement with GSK plc for the worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor being developed for the treatment of cholestatic pruritus in primary biliary cholangitis (PBC). Subsequently granted approval by the US FDA becoming the first medicine approved in the US for this indication. The approval, based on the positive GLISTEN phase III trial, provides immediate commercialisation opportunities in the US, with regulatory reviews underway in the EU, UK, Canada and China³.

Additionally, in January 2026, Alfasigma announced its investment in Innovative Molecules, obtaining the exclusive worldwide license to the parenteral formulation of adibelivir for the treatment of Herpes Simplex Virus (HSV) encephalitis, an ultra-rare and life-threatening condition.

The company is well-positioned to drive future organic growth as well through expanding its pipeline of opportunities. This includes delivering on the full potential of Jyseleca®, with application submitted following the reporting period, and being under review by EMA for the use of Jyseleca® in a new indication of treatment for axial spondyloarthritis (axSpA), a chronic inflammatory arthritis primarily affecting the spine and sacroiliac joints, causing chronic pain and stiffness that often begins in early adulthood. A disease with high prevalence in Europe, only around 40-50% of patients with axSpA achieve an adequate response with current advanced therapies, highlighting significant unmet needs.

Chairman Stefano Golinelli stated, “I am proud of our progress over 2025. We delivered solid results, advancing our strategy to drive sustainable growth and to develop meaningful solutions to patients worldwide. Alfasigma’s continued investment in innovation, partnerships, talent, capabilities, and our portfolio, positions the Company for even greater success in the years ahead.”

CEO Francesco Balestrieri commented, “Our 2025 financial results are testament to Alfasigma’s strategic direction, reflecting the strength of our existing and expanding product portfolio, particularly across Growth Markets. The US and Italy remain important markets, and the Company’s performance shows that where we invest, we grow. We are financially strong and well-capitalised, underpinning our capacity to invest across key markets and products with potential – at pace and with agility – as we advance our portfolio for continued profitable growth.”

Capitalised for Future Growth

Over 2025, Alfasigma completed successful financing rounds to support its R&D, and to accelerate growth, transformation, and global expansion. This included, but was not limited to, European Investment Bank and SACE, as well as several Italian private banks.

Forward Momentum and Sustainable Growth

Looking ahead, Alfasigma is well-placed to capitalise on its 2025 performance. Today, the company is in a significantly stronger position, with revamped growth in Consumer Healthcare and Established platforms, as well as new Rare and Specialty platforms. Leveraging its portfolio and growing presence across markets worldwide, Alfasigma is equipped to drive future growth and offer significant headroom for value creation through a disciplined M&A strategy.

About Alfasigma

Alfasigma is a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered today in Bologna and Milan. The Group’s products are distributed in more than 100 markets worldwide. Alfasigma operates offices across major European countries, as well as in the United States, China, and Mexico; production facilities in Italy, Spain, and the United States; and R&D laboratories located in Italy.

The company employs approximately 4,000 professionals dedicated to the research, development, production, and distribution of medicinal products. Its portfolio ranges from consumer healthcare products and primary care treatments to specialty and rare disease medications, with key therapeutic areas including gastroenterology, vascular health, and immunology.

1Like-for-like comparison considering Jyseleca® business acquisition timing in 2024.

2Adjusted EBITDA – adjusted EBITDA excludes the impact of restructuring costs and selected items related to Jyseleca® business acquisition.

3This transaction is ongoing and is subject to customary conditions, including applicable regulatory agency clearances such as under the Hart-Scott-Rodino Act in the US.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260330615597/en/

Contact

For further information, contact:

Global Press office:

Tristan Peniston-Bird
tristan.peniston-bird@omc.com

Irene Lawlor
Irene.Lawlor@alfasigma.com

AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial

AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that the company has initiated enrollment for the fourth cohort in its Phase 1/2 ASPIRE-FTD clinical trial evaluating AVB-101, its investigational gene therapy being developed for people living with frontotemporal dementia with GRN mutations (FTD-GRN).

AVB-101 is a differentiated and precise approach to restoring progranulin in the brain of FTD-GRN patients. AVB-101 is delivered using a minimally invasive, stereotactic neurosurgical procedure directly to the part of the brain called the thalamus. The thalamus has extensive connections to other parts of the brain, including the frontal and temporal lobes, which play a critical role in FTD and the symptoms that impact patients and their families. This targeted delivery method aims to safely and effectively cross the blood-brain barrier, delivering targeted treatment directly to the brain to restore progranulin levels in the frontal and temporal cortex where it is needed most, while at the same time minimizing the dose required and thereby limiting any potential systemic exposure.

To date, the ASPIRE-FTD trial has completed three dose-escalation cohorts with the dosing of 12 patients from five countries across three continents. ASPIRE-FTD now has 20 active trial sites across the United States, United Kingdom, Canada and in six European countries. Early data demonstrate dose dependent elevations in the key biomarker of cerebrospinal fluid (CSF) progranulin. The overall safety profile of AVB-101 remains favorable with no need for prophylactic or reactive immunosuppression. To date, there have been no serious adverse events related to AVB-101. AviadoBio plans to present additional data at the Alzheimer’s Association International Conference (AAIC) meeting in July 2026 and the International Society for Frontotemporal Dementias (ISFTD) meeting in October 2026.

Through the Treat FTD Fund, AviadoBio recently received an investment from The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) to support continued development of AVB-101 in the ASPIRE-FTD clinical trial. The Treat FTD Fund, launched in 2016 by the ADDF and the AFTD, invests in clinical studies aimed at developing novel treatments or biomarkers for FTD disorders.

“We are focused on continuing to advance AVB-101 building on the encouraging data we’ve seen so far,” said Lisa Deschamps, Chief Executive Officer, AviadoBio. “We are thrilled to now have the ADDF and the AFTD’s support on this important mission as we progress the ASPIRE-FTD trial. We are deeply committed to developing new options for patients and families affected by FTD, where significant unmet need remains.”

AviadoBio holds full worldwide rights to develop and commercialize AVB-101 in FTD-GRN and other potential indications, following the expiration of Astellas’ 2024 exclusive option and license agreement. Astellas remains a shareholder in AviadoBio.

About AviadoBio

AviadoBio is relentlessly chasing cures by developing and translating groundbreaking science and precision delivery into life-changing medicines across neurodegenerative diseases. Powered by a precision approach built on three integrated levels — payload, target and delivery — the company is advancing a pipeline of targeted, one-time AAV gene therapies across frontotemporal dementia with GRN mutations (FTD-GRN), retinitis pigmentosa (RP) and other retinal dystrophies, as well as Alzheimer’s disease and related tauopathies.

Founded in 2019 from pioneering research at King’s College London and the UK Dementia Research Institute, AviadoBio combines deep neuroscience expertise with proven biopharma leadership. Its capabilities include gene supplementation, optogenetics, and its proprietary vMiX™ RNA gene-silencing platform, enabling durable, disease-modifying approaches across multiple degenerative conditions. Headquartered in London, the company operates across the UK and the U.S. and is backed by leading global life sciences investors and strategic partners.

For more information, visit aviadobio.com and follow AviadoBio on X and LinkedIn.

About ASPIRE-FTD

ASPIRE-FTD is a Phase 1/2 open-label, multi-center study designed to evaluate the safety and preliminary efficacy of AVB-101 in patients with FTD-GRN. In the study, eligible patients receive a one-time administration of AVB-101 delivered as a set of MRI-guided infusions into the thalamus during a minimally invasive stereotactic neurosurgical procedure at an expert neurosurgical center. The ASPIRE-FTD clinical trial is currently open at trial sites in Belgium, Canada, Italy, the Netherlands, Poland, Spain, Sweden, the United Kingdom, and the United States.

More information about the ASPIRE-FTD study can be found at www.aspire-ftd.com or https://clinicaltrials.gov/study/NCT06064890.

About The Alzheimer’s Drug Discovery Foundation (ADDF)

Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation is dedicated to rapidly accelerating the development of drugs to prevent, treat, and cure Alzheimer’s disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer’s, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF’s leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer’s PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded nearly $400 million to fund 792 Alzheimer’s drug development, biomarker, and prevention programs in 21 countries. To learn more, please visit: http://www.alzdiscovery.org/.

About The Association for Frontotemporal Degeneration (AFTD)

Online at theaftd.org, AFTD is the largest national nonprofit devoted to providing resources to help families affected by FTD today, and advancing research to foster accurate diagnosis, treatments, and a cure. Our volunteer-founded organization – driven by thousands of volunteers and donors – reflects a community’s profound determination to #endFTD.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260330432799/en/

Contact

Media
Farah Speer
SVP, Head of Communications and External Relations
fspeer@aviadobio.com
+1-312-543-2881

Abstract

AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial

FuneralExperts.com Joins Forces with NotifyNOW and InheritNOW to Transform Support for Bereaved Families Across the UK

FuneralExperts.com, the UK’s leading independent and impartial frontline bereavement support service, has announced a new partnership with The Estate Registry’s services NotifyNOW and InheritNOW to transform the way families are supported following a death – helping them notify organisations efficiently and access vital financial assistance before probate is granted.

Through the partnership, families supported by FuneralExperts.com will be able to use NotifyNOW’s secure digital service to inform multiple organisations of a death in one step, removing the stress of repeated phone calls and paperwork.

Crucially, those dealing with the death of a loved one will also be supported through InheritNOW, which enables families to access funds to help cover immediate costs such as funeral expenses and essential living needs before the estate is finalised.

The collaboration brings together organisations with a shared mission: to remove unnecessary complexity, stress and financial hardship from the bereavement process, and to ensure families are treated with dignity, clarity and compassion.

FuneralExperts.com works nationwide in partnership with NHS Trusts, local authorities, coroners, hospices and care providers, offering free, independent advice and support to people navigating death, bereavement and funeral arrangements.

The organisation’s trained advisers support families with compassion and clarity at a time of loss, offering emotional support, practical assistance and clear, reliable information. This includes impartial funeral planning, welfare benefits advice, and help with essential tasks such as contacting organisations and accessing specialist bereavement support.

Joanne Regan, Director of Operations at FuneralExperts.com, said: “Too many families face unnecessary distress after a death — struggling to understand what to do next, who to contact, and how to cope financially. This partnership allows us to remove barriers at exactly the moment people need help the most.

“By combining our frontline support with the power of NotifyNOW and InheritNOW, we can ensure families are not left chasing organisations or worrying about money while they grieve. It’s about dignity, compassion and making sure no one is left to navigate this process alone.”

NotifyNOW enables families to notify more than 2,000 organisations — including banks, utilities, insurers and service providers — through a single secure process, while InheritNOW provides access to funds before probate to help cover urgent costs.

Together, both services – provided by The Estate Registry – represent a significant step forward in enhancing bereavement support in the UK.

Phil Hickson, Senior Vice President of Partnerships at The Estate Registry, said: “Through NotifyNOW and InheritNOW, we are ensuring families can deal with practical and financial matters simply, securely and with dignity – without being overwhelmed by forms, phone calls or uncertainty.

“By working in partnership with organisations like FuneralExperts.com, we are helping to build a more compassionate, joined-up system of support — one that recognises the emotional reality of bereavement while providing clear, practical solutions when families need them most.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20260330572067/en/

Contact

For more information:
Contact
For The Estate Registry – eithne@timreidmedia.com
For FuneralExperts.com – joanne.regan@funeralexperts.com

TweetText

“By combining FuneralExperts.com frontline support with the power of NotifyNOW and InheritNOW, we can ensure families are not left chasing organisations or worrying about money while they grieve.”

Provation Introduces Real-Time, AI-Powered Documentation Assist for GI Procedures

Provation, a leading provider of clinical productivity software, announces the launch of Provation^® Mira Documentation Assist, a voice-driven documentation capability within its cloud-based GI procedure platform, Provation^® Apex, enabling real-time structured documentation during procedures.

This hands-free technology allows clinicians to document in real-time by simply speaking, reducing the need for manual data entry and post-procedure recall.

“Mira brings documentation directly into the procedure flow. By capturing key elements in real-time, it reduces the need for physicians to recall and reconstruct details after the case,” said Executive Medical Director, Lukasz Kowalczyk, MD.

Clinicians using Provation Mira Documentation Assist are already seeing its impact firsthand.

“Mira has drastically evolved what I do in between patients… At optimal efficiency, I’m not typing or clicking at all in between the cases I’m reviewing. I would say about 75% less time now with Mira,” said Neil D. Parikh, MD.

By leveraging advanced AI algorithms, Provation Mira Documentation Assist listens to physician narration and converts it into structured clinical documentation—preserving the data integrity required for coding, reporting, and quality programs while reducing the need for post-procedure recall.

Bringing AI-Powered Innovation to GI Documentation

“A significant portion of the documentation burden in procedural care comes from having to remember and reconstruct details after the case,” said Ankush Kaul, President of Provation.

“Mira addresses that by capturing key elements of the procedure in real time—reducing cognitive load for physicians while preserving the structured, high-quality documentation our customers depend on.

It’s a meaningful step toward a more intelligent, workflow-native platform – where documentation increasingly happens in the moment of care, not after it.”

Key Benefits of Provation Apex Mira Documentation Assist:

• Reduced Cognitive Burden – Captures key procedural elements in real time, minimizing reliance on post-procedure recall.
• Improved Workflow Efficiency – Reduces documentation effort between cases, allowing clinicians to stay focused and maintain flow throughout the day.
• Stronger Revenue Integrity – Structured, real-time documentation supports faster and more accurate coding and submission.

Designed specifically for the needs of GI providers, Provation Mira Documentation Assist represents the next step in AI-driven efficiency, ensuring reliable, accurate, and standardized documentation. As the healthcare industry continues to embrace AI-powered innovations, Provation remains at the forefront, delivering solutions that maximize quality and productivity.

Mira represents an important step in Provation’s broader vision to deliver an intelligent platform that integrates documentation seamlessly into the clinical workflow.

For more information about Provation Apex’s latest feature, visit www.provationmedical.com/apex-mira-documentation-assist/

About Provation

Provation is a leading healthcare software provider dedicated to empowering providers with innovative solutions that streamline clinical workflows in the Gastroenterology and Anesthesia specialties. Provation’s platforms, Provation^® Apex and Provation^® iPro, are trusted by over 5,000 hospitals, surgery centers, and medical offices globally. With a purpose-driven approach, Provation continues to drive productivity and improve patient outcomes through advanced documentation and workflow solutions. For more information, visit provationmedical.com and follow us on Twitter, Facebook, and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260330865344/en/

Contact

Sami Ernster
Content Marketing Specialist
sami.ernster@provationmedical.com

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote

The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company’s total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission’s decision to cease mediation, the union has now secured the legal mandate to strike.

The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations.

Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea’s major broadcaster, MBC, in November 2025. The union believes this crisis stems from management’s failure to address risks that could have been mitigated earlier, viewing it as a critical compliance risk.

Furthermore, despite Samsung Biologics reporting a 56.6% year-over-year increase in operating profit, management offered wage conditions falling below last year’s. The union argues this exposes a lack of independent bargaining authority, as management rigidly adhered to a 4.1% group-level wage guideline dictated by its parent company, Samsung Electronics, ignoring the company’s own record earnings.

“A strike is a constitutionally protected and necessary tool to bring management to the negotiating table,” said Jaesung Park, President of the Samsung Biologics Labor Union. “In the global Contract Development and Manufacturing Organization (CDMO) industry, unresolved labor disputes and compliance issues directly threaten the supply chain of our international clients. Ultimately, our strike is aimed at correcting these governance failures and promoting a more transparent and accountable corporate environment.”

As the majority representative body, the union declared that unless management presents a credible and autonomous proposal, it plans to initiate phased strike actions, starting with an offline rally on April 22, leading up to a potential general strike on May 1.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260330741758/en/

Contact

Media Contact:
Jaesung Park, President, Samsung Biologics Labor Union
Email: js002.park@samsung.com
Phone: +82-10-4133-5744

Abstract

Samsung Biologics Labor Union secured a strike mandate, warning that governance failures and rigid management pose CDMO supply chain risks.

TweetText

Unresolved governance failures and rigid labor policies at Samsung Biologics now pose a structural supply chain risk to global CDMO clients.

AngloGold Ashanti Holdings plc Announces Capped Cash Tender Offers for Part of Its 3.375% Notes Due 2028, 3.750% Notes Due 2030 and 6.500% Notes Due 2040

AngloGold Ashanti Holdings plc (the “Offeror”), a company incorporated under the laws of the Isle of Man, announces today the offers to purchase for cash the outstanding series of its (i) 3.375% notes due 2028 (the “2028 Notes”), (ii) 3.750% notes due 2030 (the “2030 Notes”) and (iii) 6.500% notes due 2040 (the “2040 Notes” and together with the 2028 Notes and the 2030 Notes, the “Notes”), issued by the Offeror and guaranteed by AngloGold Ashanti plc, a company incorporated under the laws of England and Wales (“AGA”) (the “Offers”) in accordance with the acceptance priority levels set forth in the table below (the “Acceptance Priority Levels”), with “1” being the highest Acceptance Priority Level and “3” being the lowest Acceptance Priority Level, subject to an aggregate purchase price (exclusive of Accrued Interest (as defined below)) for the 2040 Notes that does not exceed $50,000,000 (as such amount may be increased or decreased by the Offeror, the “Sub-Cap”), and for an aggregate purchase price (exclusive of Accrued Interest) for all series of Notes of up to $650,000,000 (as such amount may be increased or decreased by the Offeror, the “Aggregate Cap”). Subject to the Aggregate Cap and the Sub-Cap, the amount of a series of Notes that is purchased in the relevant Offer on the Early Settlement Date or Final Settlement Date (each as defined below), as applicable, will be based on the Acceptance Priority Level for such series of Notes and will be subject to the proration arrangements applicable to the Offers. The terms and conditions of the Offers are described in an offer to purchase dated March 30, 2026 (the “Offer to Purchase”).

Capitalized terms not otherwise defined in this announcement have the same meaning as assigned to them in the Offer to Purchase.

Holders are advised to read carefully the Offer to Purchase for full details of, and information on the procedures for participating in, the Offers.

The following table sets forth certain information relating to pricing for the Offers.

Title of Security

ISIN / CUSIP

Principal Amount Outstanding

Maturity Date

Sub-Cap

Acceptance Priority Level

Reference U.S. Treasury Security

Fixed Spread (basis points)(1)

Bloomberg Reference Page

Early Tender Payment(2)

3.375% notes due 2028

US03512TAF84 / 03512TAF8

$750,000,000

November 1, 2028

N/A

1

UST 3.500% due March 15, 2029

50

FIT 1

$50

3.750% notes due 2030

US03512TAE10 / 03512TAE1

$700,000,000

October 1, 2030

N/A

2

UST 3.875% due March 31, 2031

50

FIT 1

$50

6.500% notes due 2040

US03512TAB70 / 03512TAB7

$300,000,000

April 15, 2040

$50,000,000(3)

3

UST 4.125% due February 15, 2036

140

FIT 1

$50

(1)		The applicable Total Consideration shall be calculated with reference to the Fixed Spread in respect of the relevant series of Notes set out above and includes the Early Tender Payment (each capitalized term, as defined below). Each Total Consideration will be calculated with reference to the relevant maturity date (or, as specified in the Offer to Purchase, the par call date) of the relevant Notes.
(2)		Per $1,000 principal amount of Notes validly tendered and received by Kroll Issuer Services Limited (the “Information & Tender Agent”) at or prior to the Early Tender Time (as defined below) and accepted for purchase (and subject to the applicable Minimum Authorized Denomination (as specified below)). The applicable Total Consideration, when calculated with reference to the Fixed Spread in respect of the relevant series of Notes set out above, already includes the Early Tender Payment. The applicable Late Tender Offer Consideration (as defined below) for Notes validly tendered and received by the Information & Tender Agent after the Early Tender Time but at or prior to the Expiration Time (as defined below) and accepted for purchase will be the applicable Total Consideration minus the Early Tender Payment.
(3)		The aggregate maximum purchase price payable (exclusive of Accrued Interest) for the 2040 Notes pursuant to the relevant Offer is subject to a Sub-Cap of $50,000,000.

The Offers

The Offeror will pay Total Consideration for each $1,000 principal amount of each series of Notes validly tendered and not validly withdrawn at or prior to the Early Tender Time and accepted for purchase by the Offeror (subject to the applicable Minimum Authorized Denomination (as defined below)) calculated in accordance with the formula set out in the Offer to Purchase in a manner that will be equal to an amount (rounded to the nearest cent, with half a cent rounded upwards) that would reflect, as of the Early Settlement Date, a yield to the maturity date (or, as specified in the Offer to Purchase, the par call date) of such series of Notes equal to the sum of:

• the “Reference Yield” for such series of Notes, being the bid-side yield (rounded to the nearest 0.001% with 0.0005% being rounded upwards) on the Reference U.S. Treasury Security for such series of Notes calculated from the applicable bid-side price by the Dealer Managers (as defined below) in accordance with standard market practice as of the Tender Price Determination Time, as displayed for the Reference U.S. Treasury Security on the Reference Page set forth in the table above (in respect of each series of Notes, the “Reference U.S. Treasury Security”), plus

• the applicable fixed spread for such series of Notes as specified in the table above (the “Fixed Spread”).

The sum of the Fixed Spread and the Reference Yield is referred to as the “Yield.” Specifically, the Total Consideration for each series of Notes will equal (i) the value of all remaining payments of principal and interest on such series of Notes up to and including maturity date (or, as specified in the Offer to Purchase, the par call date) of such series of Notes discounted to the Early Settlement Date at a discount rate equal to the sum of (x) the Reference Yield for such series of Notes plus (y) the Fixed Spread for such series of Notes, minus (ii) Accrued Interest to the Early Settlement Date for such series of Notes.

For the applicable series of Notes, at the Tender Price Determination Time, if the Yield as determined in accordance with the Offer to Purchase is less than the contractual annual rate of interest for such series of Notes, then such Total Consideration will be calculated based on the par call date; if the Yield as determined in accordance with the Offer to Purchase is higher than or equal to the contractual annual rate of interest for such series of Notes, then such Total Consideration will be calculated based on the maturity date. For the avoidance of doubt, the Total Consideration with respect to the 2040 Notes will be calculated based on the maturity date because the 2040 Notes are not redeemable at par prior to their maturity under the terms of the 2040 Notes.

The Total Consideration in respect of each series of Notes, when calculated in the manner set out above, already includes the early tender payment of $50 per $1,000 principal amount of such Notes (the “Early Tender Payment”). To receive the applicable Total Consideration, which includes the Early Tender Payment, holders must validly tender and not validly withdraw their Notes so that they are received by the Information & Tender Agent at or prior to 5:00 p.m., New York City time, on April 13, 2026, unless extended (such time, as the same may be extended, the “Early Tender Time”). Holders that validly tender Notes which tender is received by the Information & Tender Agent following the Early Tender Time, but at or prior to the Expiration Time, and whose Notes are accepted for purchase, will receive only the applicable Late Tender Offer Consideration, which is an amount equal to the applicable Total Consideration minus the Early Tender Payment.

In addition to the relevant Late Tender Offer Consideration or Total Consideration, as applicable, all Holders of Notes of a series accepted for purchase will also receive accrued and unpaid interest on such series of Notes from the last interest payment date up to, but not including, the Early Settlement Date or the Final Settlement Date (as specified below), as applicable (the “Accrued Interest”).

Holders should be aware that the expected Final Settlement Date (expected to be May 1, 2026) coincides with a regular scheduled interest payment date for the 2028 Notes. As such, Accrued Interest on any 2028 Notes tendered after the Early Tender Time but before the Expiration Time and accepted for purchase by the Offeror will be paid pursuant to the usual payment process in the ordinary course of business and not in the context of the applicable Offer for such Notes. As such, no Accrued Interest shall be payable pursuant to the applicable Offer in respect of the 2028 Notes tendered after the Early Tender Time but before the Expiration Time, unless the Final Settlement Date is amended to a date which is not a regular scheduled interest payment date for the 2028 Notes. Accrued interest on the 2030 Notes and the 2040 Notes will be paid on the regular interest payment dates for such series of Notes (including, April 1, 2026 with respect to the 2030 Notes and April 15, 2026 with respect to the 2040 Notes) in accordance with the terms of such Notes and pursuant to the usual payment process in the ordinary course of business, and in the context of the applicable Offer, in accordance with the terms of the Offer to Purchase.

Holders of Notes that are validly tendered and not validly withdrawn at or prior to the Early Tender Time and that are accepted for purchase will receive the applicable Total Consideration plus Accrued Interest on the Early Settlement Date (subject to the right of the Offeror to extend the Early Tender Time and delay the acceptance of Tender Instructions as set out in the Offer to Purchase). The Early Settlement Date will be promptly following the Early Tender Time and is expected to be April 16, 2026, the third business day after the Early Tender Time. Holders of Notes that are validly tendered following the Early Tender Time but at or prior to the Expiration Time and that are accepted for purchase will receive the applicable Late Tender Offer Consideration plus Accrued Interest on the Final Settlement Date (subject to the right of the Offeror to extend the Expiration Time and delay the acceptance of Tender Instructions as set out in the Offer to Purchase). The Final Settlement Date will be promptly following the Expiration Time and is expected to be May 1, 2026, the third business day after the Expiration Time.

Tender Instructions must be submitted in respect of a principal amount of Notes of no less than the Minimum Authorized Denomination and may be submitted in respect of integral multiples of $1,000 above such Minimum Authorized Denomination. The “Minimum Authorized Denomination” is $200,000 for the 2028 Notes and the 2030 Notes and $1,000 for the 2040 Notes.

Subject to the Aggregate Cap, the Sub-Cap, the proration arrangements applicable to the Offers and subject to the satisfaction or waiver of the Conditions to the Offers, all Notes validly tendered on or prior to the Early Tender Time having a higher Acceptance Priority Level (with “1” being the highest Acceptance Priority Level and “3” being the lowest Acceptance Priority Level) will be accepted for purchase before any tendered Notes having a lower Acceptance Priority Level are accepted for purchase, and all Notes validly tendered after the Early Tender Time having a higher Acceptance Priority Level will be accepted for purchase before any Notes tendered after the Early Tender Time having a lower Acceptance Priority Level are accepted for purchase. However, subject to the Aggregate Cap and the Sub-Cap, Notes validly tendered on or prior to the Early Tender Time will be accepted for purchase in priority to any Notes tendered after the Early Tender Time even if such Notes tendered after the Early Tender Time have a higher Acceptance Priority Level than Notes tendered on or prior to the Early Tender Time.

The Offeror’s obligation to accept for purchase and to pay for Notes validly tendered pursuant to each Offer is subject to the satisfaction or waiver of the Conditions described in the Offer to Purchase. The Offers are not conditioned on any minimum amount of Notes being tendered. Subject to applicable law, the Offeror expressly reserves the right, in its sole discretion, to terminate any of the Offers with respect to the Notes if the conditions to the Offers are not satisfied.

If the Offeror is required to make an announcement relating to an extension of the Withdrawal Deadline, the Early Tender Time or the Expiration Time, an amendment or termination of the Offers, the results of proration of any series of Notes, or acceptance of the Notes of any series for purchase, the Offeror will do so as promptly as practicable and, in the case of an extension of the Expiration Time, no later than 9:00 a.m., New York City time, on the business day after the previously scheduled Expiration Time. Announcements in connection with the Offers will be made by issuing a press release to a widely disseminated news or wire service. Copies of all announcements, notices and press releases will be available from the Information & Tender Agent. All documentation relating to the Offers, together with any updates, will also be available (subject to eligibility confirmation and registration) on the Offer Website https://deals.is.kroll.com/anglogoldashanti operated by the Information & Tender Agent for the purpose of the Offers.

A tender of Notes for purchase pursuant to the Offers should be made by the submission of a valid Tender Instruction. A separate Tender Instruction must be submitted on behalf of each beneficial owner of the Notes and in respect of each series of Notes. Tenders and instructions other than in accordance with the procedures set out in the Offer to Purchase will not be accepted.

INDICATIVE TIMETABLE

The following table sets out the expected dates and times of the key events relating to the Offers. This is an indicative timetable and is subject to change.

Date and Time		Action
March 30, 2026		Commencement of the Offers
		Offer to Purchase available from the Information & Tender Agent and on the Offer Website.   Offers announced through a press release to a recognized financial news service in the manner described under “Terms and Conditions of the Offers—Announcements” in the Offer to Purchase.
April 13, 2026, 5:00 p.m. (New York City time), unless extended		Early Tender Time
		The deadline for Holders to validly tender Notes and for such tenders to be received by the Information & Tender Agent to be eligible for the applicable Total Consideration, which includes the Early Tender Payment, plus Accrued Interest.   The Offeror will issue a press release announcing the amount of each series of Notes validly tendered and not validly withdrawn at or prior to the Early Tender Time. Notes tendered at or prior to the Early Tender Time will be subject to acceptance ahead of, and proration on a basis more favorable to, Notes tendered thereafter.
April 13, 2026, 5:00 p.m. (New York City time), unless extended		Withdrawal Deadline
		The deadline for Holders to properly withdraw tenders of their Notes. If a tender of Notes is properly withdrawn, the Holder will not receive any consideration on the Early Settlement Date or the Final Settlement Date, as applicable (unless that Holder validly re-tenders such Notes and such re-tender is received by the Information & Tender Agent at or prior to the Early Tender Time or Expiration Time, as applicable, and the Notes are accepted by the Offeror).
April 14, 2026, 10:00 a.m. (New York City time), unless extended		Tender Price Determination Time
		The time at which the Reference Yield, the applicable Total Consideration and the applicable Late Tender Offer Consideration with respect to each series of Notes validly tendered and accepted for purchase will be determined by the Dealer Managers.   The Offeror will issue a press release announcing the Reference Yield for each series of Notes, the applicable Total Consideration and Late Tender Offer Consideration for each such series of Notes, the amount of each series of Notes validly tendered and to be accepted for purchase on the Early Settlement Date and the details of proration, if any, as soon as practicable after the determination thereof.
Expected to be April 16, 2026		Early Settlement Date
		The date on which the Offeror will deposit with DTC the amount of cash necessary to pay, and on which DTC will pay to each Holder whose Notes are accepted for purchase as at the Early Tender Time, the applicable Total Consideration, plus Accrued Interest, in respect of such Notes.
April 28, 2026, 5:00 p.m. (New York City time), unless extended		Expiration Time
		The deadline for Holders to validly tender Notes and for such tenders to be received by the Information & Tender Agent to be eligible for the applicable Late Tender Offer Consideration, plus Accrued Interest.   The Offeror will, if applicable, issue a press release announcing the amount of each series of Notes validly tendered after the Early Tender Time and at or prior to the Expiration Time and the amount of each such series of Notes to be accepted for purchase as soon as reasonably practicable after the Expiration Time.
Expected to be May 1, 2026		Final Settlement Date
		If applicable, the date on which the Offeror will deposit with DTC the amount of cash necessary to pay, and on which DTC will pay to each Holder whose Notes are accepted for purchase but have not been previously purchased, the applicable Late Tender Offer Consideration, plus Accrued Interest in respect of such Notes.

The Offeror expressly reserves the right, in its sole discretion, subject to applicable law, to (i) terminate any or all of the Offers and not accept for purchase any Notes of the relevant series tendered pursuant to any such Offer if any of the Conditions to any such Offer are not satisfied or waived, (ii) waive any and all of the Conditions to any Offer, (iii) extend the Early Tender Time or the Expiration Time with respect to any Offer, (iv) change the Withdrawal Deadline, the Early Settlement Date and/or the Final Settlement Date with respect to any Offer or (v) otherwise amend the other terms of any or all of the Offers, including increasing or decreasing the Aggregate Cap and/or the Sub-Cap and changing the Acceptance Priority Levels with respect to any of the series of Notes. In the event that any Offer is terminated or otherwise not completed, the Total Consideration or the Late Tender Offer Consideration, as applicable, and any Accrued Interest, relating to the Notes subject to such Offer will not be paid or become payable pursuant to the Offers, without regard to whether Holders have validly tendered their Notes (in which case such tendered Notes will be promptly returned to the Holders).

Holders of Notes are advised to read carefully the Offer to Purchase for full details of and information on the procedures for participating in the Offers.

FURTHER INFORMATION

Holders of Notes may access the Offer to Purchase (subject to eligibility confirmation and registration) at https://deals.is.kroll.com/anglogoldashanti.

Questions and requests for assistance in connection with the Offers may be directed to the Dealer Managers:

Citigroup Global Markets Limited Citigroup Centre Canada Square, Canary Wharf London E14 5LB United Kingdom Attention: Liability Management Group In Europe: +44 20 7986 8969 In the United States: Toll Free: +1 800 558 3745 Collect: +1 212 723 6106 Email: liabilitymanagement.europe@citi.com

Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 United States Attention: Liability Management Group Toll Free: +1 (800) 828-3182 Europe: +44 207 7744836 Email: Liabilitymanagement.eu@gs.com

Questions and requests for assistance in connection with the tender of Notes including requests for a copy of the Offer to Purchase may be directed to:

INFORMATION & TENDER AGENT Kroll Issuer Services Limited The News Building 3 London Bridge Street London SE1 9SG United Kingdom Attention: Owen Morris Telephone: +44 20 7704 0880 E-mail: anglogoldashanti@is.kroll.com Offer Website: https://deals.is.kroll.com/anglogoldashanti

NOTICE AND DISCLAIMER

Subject to applicable law, the Offeror or any of its affiliates may, at any time and from time to time, acquire Notes, other than pursuant to the Offers, through open market or privately negotiated transactions, through tender offers, exchange offers, redemptions or otherwise, or the Offeror may redeem Notes pursuant to their terms to the extent that such Notes then permit redemption. Any future purchases of Notes may be on the same terms or on terms that are more or less favorable to Holders of Notes than the terms of the Offers, and could be for cash or other consideration.

This announcement must be read in conjunction with the Offer to Purchase. This announcement and the Offer to Purchase contain important information which must be read carefully before any decision is made with respect to the Offers. If any Holder is in any doubt as to the action it should take or is unsure of the impact of the Offers, it is recommended to seek its own financial and legal advice, including as to any tax consequences, from its stockbroker, bank manager, attorney, accountant or other independent financial or legal adviser. Any individual or company whose Notes are held on its behalf by a broker, dealer, bank, custodian, trust company or other nominee or intermediary must contact such entity if it wishes to tender Notes in the Offers (or to validly withdraw any such tender). None of the Offeror, the Dealer Managers, the Information & Tender Agent or any person who controls, or is a director, officer, employee or agent of such persons, or any affiliate of such persons, makes any recommendation as to whether Holders of Notes should participate in the Offers.

Cautionary Statement

Certain statements contained in this document, other than statements of historical fact, including, without limitation, those concerning the economic outlook for the gold mining industry, expectations regarding gold prices, production, mine life, total cash costs, all-in sustaining costs, cost savings and other operating results, return on equity, productivity improvements, growth prospects, preliminary financial and production metrics for in-process projects, the ability to convert mineral resource into mineral reserve and replace mineral reserves net of depletion from production and outlook of AGA’s operations, individually or in the aggregate, including the achievement of project milestones, commencement and completion of commercial operations of certain of AGA’s exploration and production projects and the completion of acquisitions, dispositions or joint venture transactions, AGA’s liquidity and capital resources and capital expenditures and the outcome and consequences of any potential or pending litigation or regulatory proceedings or environmental health and safety issues, are forward-looking statements regarding AGA’s financial reports, operations, economic performance and financial condition. These forward-looking statements or forecasts involve known and unknown risks, uncertainties and other factors that may cause AGA’s actual results, performance, actions or achievements to differ materially from the anticipated results, performance, actions or achievements expressed or implied in these forward-looking statements. Although AGA believes that the expectations reflected in such forward-looking statements and forecasts are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results, performance, actions or achievements could differ materially from those set out in the forward-looking statements as a result of, among other factors, changes in economic, social, political and market conditions, including related to inflation or international conflicts, the success of business and operating initiatives, changes in the regulatory environment and other government actions, including environmental approvals, fluctuations in gold prices and exchange rates, the outcome of pending or future litigation proceedings, any supply chain disruptions, any public health crises, pandemics or epidemics, the failure to maintain effective internal control over financial reporting or effective disclosure controls and procedures, the inability to remediate one or more material weaknesses, or the discovery of additional material weaknesses, in AGA’s internal control over financial reporting, and other business and operational risks and challenges and other factors, including mining accidents. For a discussion of such risk factors, refer to AGA’s annual report on Form 20-F for the year ended December 31, 2025, which has been filed with the United States Securities and Exchange Commission (the “SEC”). These factors are not necessarily all of the important factors that could cause AGA’s actual results, performance, actions or achievements to differ materially from those expressed in any forward-looking statements. Other unknown or unpredictable factors could also have material adverse effects on AGA’s future results, performance, actions or achievements. Consequently, readers are cautioned not to place undue reliance on forward-looking statements. AGA undertakes no obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except to the extent required by applicable law. All subsequent written or oral forward-looking statements attributable to AGA or any person acting on its behalf are qualified by the cautionary statements herein.

OFFER AND DISTRIBUTION RESTRICTIONS

This announcement and the Offer to Purchase do not constitute an offer or an invitation to participate in the Offers in any jurisdiction in which, or to any person to or from whom, it is unlawful to make such offer or invitation or for there to be such participation under applicable laws. The distribution of this announcement and the Offer to Purchase in certain jurisdictions may be restricted by law. Persons into whose possession this announcement or the Offer to Purchase comes are required by the Offeror, the Dealer Managers and the Information & Tender Agent to inform themselves about and to observe any such restrictions.

United Kingdom

The Offer to Purchase and any other documents or materials relating to the Offers are only addressed to Holders where they would (if they were clients of the Offeror) be per se professional clients or per se eligible counterparties of the Offeror within the meaning of the rules of the Financial Conduct Authority (“FCA”). Neither the Offer to Purchase nor any other related documents or materials are addressed to or directed at any persons who would be retail clients within the meaning of the FCA rules and any such persons should not act or rely on them. Recipients of the Offer to Purchase and any other documents or materials relating to the Offers should note that the Offeror is acting on its own account in relation to the Offers and will not be responsible to any other person for providing the protections which would be afforded to clients of the Offeror or for providing advice in relation to the Offers.

This announcement, the Offer to Purchase and any other documents or materials relating to the Offers are not being made and such documents have not been approved by an authorized person for the purposes of section 21 of the Financial Services and Markets Act 2000. Accordingly, such documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. The communication of the Offer to Purchase, and any other documents or materials relating to the Offers, is exempt from the restriction on financial promotions under section 21 of the FSMA on the basis that it is only directed at and may only be communicated to persons falling within the definition of investment professionals (as defined by Article 19(5) of the Financial Promotion Order) or persons who are within Article 43 of the Financial Promotion Order, and any other persons to whom they may otherwise lawfully be communicated under the Financial Promotion Order.

EEA

In the EEA, this announcement and the Offers will not, directly or indirectly, be made to, or for the account of, any person other than to qualified investors within the meaning of Article 2(e) of the Prospectus Regulation.

Neither this announcement nor the Offer to Purchase, nor any other documentation or material relating to the Offers, has been or will be submitted to a competent authority in the EEA for approval. Therefore, neither the Offer to Purchase nor any other documentation or material relating to the Offers qualify as an approved prospectus as meant in Article 6 of the Prospectus Regulation.

Accordingly, in the EEA, the Offers may not be made by way of an “offer of securities to the public” within the meaning of Article 2(d) of the Prospectus Regulation and the Offers may not be promoted and are not being made to, any person in the EEA (with the exception of “qualified investors” within the meaning of Article 2(e) in conjunction with Article 1(4)(a) of the Prospectus Regulation). This announcement, the Offer to Purchase and any other documentation or materials relating to the Offers (including memoranda, information circulars, brochures or similar documents) have not been forwarded or made available to, and are not being forwarded or made available to, directly or indirectly, any such person.

With regard to the EEA, this announcement and the Offer to Purchase have been transmitted only for personal use by the aforementioned qualified investors and only for the purpose of the Offers. Accordingly, the information contained in this announcement and the Offer to Purchase may not be used for any other purpose or be transmitted to any other person in the EEA.

Belgium

None of this announcement, the Offer to Purchase or any other documents or materials relating to the Offers have been submitted to or will be submitted for approval or recognition to the Belgian Financial Services and Markets Authority (Autorité des services marches financiers / Autoriteit voor financiële diensten en markten) and, accordingly, the Offers may not be made in the Kingdom of Belgium by way of a public offering, as defined in Articles 3 and 6 of the Belgian Law of April 1, 2007 on public takeover bids as amended or replaced from time to time. Accordingly, the Offers may not be advertised and the Offers will not be extended, and none of this announcement, the Offer to Purchase or any other documents or materials relating to the Offers (including any memorandum, information circular, brochure or any similar documents) has been or shall be distributed or made available, directly or indirectly, to any person in the Kingdom of Belgium other than “qualified investors” in the sense of Article 2(e) of the Prospectus Regulation, acting on their own account. This announcement and/or the Offer to Purchase have been issued only for the personal use of the above qualified investors and exclusively for the purpose of the Offers. Accordingly, the information contained in this announcement and/or Offer to Purchase may not be used for any other purpose or disclosed to any other person in the Kingdom of Belgium.

France

This announcement, the Offer to Purchase and any other documents or offering materials relating to the Offers may not be distributed in the Republic of France except to qualified investors (investisseurs qualifiés) as defined in Article L.411-2 1° of the French Code monétaire et financier Article 2(e) of the Prospectus Regulation. The Offer to Purchase has not been and will not be submitted for clearance to the Autorité des marchés financiers.

Italy

None of the Offers, this announcement, the Offer to Purchase or any other documents or materials relating to the Offers have been or will be submitted to the clearance procedure of the Commissione Nazionale per le Società e la Borsa (“CONSOB”), pursuant to applicable Italian laws and regulations.

The Offers are being carried out in the Republic of Italy as an exempted offer pursuant to article 101-bis, paragraph 3-bis of the Legislative Decree No. 58 of February 24, 1998, as amended (the “Financial Services Act”) and article 35-bis, paragraph 4 of CONSOB Regulation No. 11971 of May 14, 1999, as amended (the “Issuers’ Regulation”). The Offers are also being carried out in compliance with article 35-bis, paragraph 7 of the Issuers’ Regulation.

Holders or beneficial owners of the Notes that are located in Italy can tender the Notes through authorized persons (such as investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with the Financial Services Act, CONSOB Regulation No. 20307 of February 15, 2018, as amended from time to time, and Legislative Decree No. 385 of September 1, 1993, as amended) and in compliance with applicable laws and regulations or with requirements imposed by CONSOB or any other Italian authority.

General

This announcement is for informational purposes only and shall not constitute an offer to buy, a solicitation to buy or an offer to sell any securities. The Offers are being made only pursuant to the Offer to Purchase and only in such jurisdictions as is permitted under applicable law. Please see the Offer to Purchase for certain important information on offer restrictions applicable to the Offers.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260329846914/en/

Contact

Media

Andrea Maxey
+61 08 9425 4603 / +61 400 072 199
amaxey@aga.gold

General inquiries
media@anglogoldashanti.com

Investors

Andrea Maxey
+61 08 9425 4603 / +61 400 072 199
amaxey@aga.gold

Yatish Chowthee
+27 11 637 6273 / +27 78 364 2080
yrchowthee@anglogoldashanti.com

Website: www.anglogoldashanti.com

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy

Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.²

“Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF platform, we hope to deliver a treatment that goes beyond managing symptoms and changes the course of disease, opening the door to a better future for patients and their families.”

Approximately 764,000 people in the U.S. and an estimated 712,000 people in the EU are living with CP^3,4. There are currently no approved therapies that treat the underlying brain damage of CP. Treatment often includes symptom relief and physical, occupational, and speech therapy, which can strengthen muscles, improve coordination, and support daily activities.

“The cause of CP-related disability is directly connected to NGF’s natural role in the body – supporting the growth, survival, and repair of developing nerve cells^5,6,” said Ahmed Enayetallah, Chief Development Officer at Dompé. “With intranasal NGF, Dompé aims to address CP at its source, fundamentally reshape the disease’s trajectory and improve the life-long outlook for patients.”

The Phase 2 investigational study was initiated by Dompé at the Agostino Gemelli IRCCS University Hospital Foundation and will soon be activated at the IRCCS Bambino Gesù Pediatric Hospital. The study will enroll a total of 60 children with spastic CP in 10 different centers across Italy, aged two to six years old with any severity of any level (I–V) on the Gross Motor Function Classification System – Expanded and Revised (GMFCS-E&R).

About Dompé

Dompé farmaceutici S.p.A. is a privately held, global biopharmaceutical company on a mission to bring the full potential of nerve growth factor (NGF) to patients. As the first company to unlock the therapeutic potential of NGF, Dompé developed the first FDA-approved NGF treatment. Today, our clinical pipeline reflects our commitment to redefining treatments across ophthalmic, neurological and pain-related conditions. Building on 130 years of independence, we are embracing the challenge to transform our science and ourselves by delivering first-in-class, disease-modifying therapies through NGF and other breakthrough molecules to help people improve their sight, support neurological recovery and manage pain effectively. Today, Dompé employs more than 950 employees worldwide and maintains a US commercial operations hub in the San Francisco Bay Area. Learn more at https://www.dompe.com/us/.

About Nerve Growth Factor (NGF)

Nerve Growth Factor (NGF) is a neurotrophin, a member of a family of proteins essential for the growth, maintenance and survival of neurons, with broad therapeutic potential. NGF was discovered by the Italian neurobiologist Professor Rita Levi-Montalcini and American biochemist Dr. Stanley Cohen, earning them the Nobel Prize in Physiology or Medicine in 1986. In their research, Drs. Levi-Montalcini and Cohen uncovered that NGF plays a crucial role in the proliferation, differentiation, and survival of sympathetic and sensory neurons. Dompé is the first company to unlock the therapeutic potential of NGF, building upon a Nobel Prize-winning discovery to deliver a breakthrough treatment for a rare neurotrophic eye disease.

About Cerebral Palsy (CP)

CP refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain. CP has multiple subtypes which are characterized by a range of symptoms, including but not limited to: hypertonicity, hyperreflexia, involuntary uncontrolled, repetitive movements, altered muscle tone, abnormal posture. The severity of CP presentation varies depending on the movement disorder, area affected, and extent of damage. Various factors can disrupt normal brain development and lead to CP, including infections, encephalopathy, trauma, or genetic contributions. Disruption at critical developmental stages of brain plasticity, such as in utero, during childbirth, or during infancy can lead to CP.

References:
^[1] Rosenbaum P, et al. Dev Med Child Neurol Suppl. 2007;109:8-14. https://pubmed.ncbi.nlm.nih.gov/17371509/
^[2] Salomon, I. Brain and Behavior. 2025;14(10) https://onlinelibrary.wiley.com/doi/10.1002/brb3.70065
^[3] Cerebral Palsy Guidance. Cerebral Palsy Facts and Statistics. Available at: https://cerebralpalsyguidance.com/cerebral-palsy/research/facts-and-statistics
^[4] McIntyre S; Global CP Prevalence Group*. Global prevalence of cerebral palsy: A systematic analysis. Dev Med Child Neurol. 2022 Dec;64(12):1494-1506. doi: 10.1111/dmcn.15346. Epub 2022 Aug 11. PMID: 35952356; PMCID: PMC9804547 https://pubmed.ncbi.nlm.nih.gov/35952356/
^[5] Chen X, et al. Adv Clin Exp Med. 2025;34(6):911-923. Available here.
^[6] Di Sarno L, et al. Pharmaceuticals. 2025; 18(6):929. Available here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260326265178/en/

Contact

Media:
Guido Romeo – Director Corporate Communications and Public Affairs
+39 349 4154010 / guido.romeo@dompe.com
Charlie Gould – Ruder Finn
+1 917 626 7968 / Charlie.Gould@ruderfinn.com

For enquiries about the study: cp.enquiries@dompe.com

Abstract

Dompé advances a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) for spastic cerebral palsy (CP).

TweetText

“With our emerging intranasal NGF platform, we hope to deliver a treatment that goes beyond managing symptoms and changes the course of disease, opening the door to a better future for patients and their families.”

AltynGold Plc (“AltynGold” or the “Company”) Participation in MINEX Kazakhstan 2026

AltynGold (LSE:ALTN), the Kazakh metals, mining and energy group, is pleased to announce its participation as an exhibitor at the MINEX Kazakhstan Mining & Exploration Forum 2026, taking place 14–16 April 2026 in Astana, Kazakhstan.

MINEX Kazakhstan is one of the region’s leading mining and exploration forums, bringing together government representatives, mining companies, investors and industry stakeholders to discuss developments across Central Asia’s mining sector.

Participation in MINEX Kazakhstan supports AltynGold’s strategy to increase its profile among investors and industry peers, while showcasing its key operations and growth plans.

Further information on the forum is available at: https://2026.minexkazakhstan.com/

Notes to Editors

AltynGold plc is a precious metals mining company listed on the London Stock Exchange (LSE: ALTN), focused on the exploration, development, and production of gold in Kazakhstan. The Company’s portfolio consists of two assets in Kazakhstan: Sekisovskoye and Teren-Sai. The Company’s current principal producing asset is the Sekisovskoye gold mine, located in the East Kazakhstan region. In 2024 AltynGold completed the installation and commissioning of its new processing line at Sekisovskoye, supporting its medium-term gold production target of 100,000oz.

AltynGold is pursuing an ambitious growth strategy aimed at increasing production and unlocking value across its licence area. The Company is committed to sustainable mining practices, operational efficiency, and contributing to the long-term development of the regional economy.

To read more about AltynGold please visit our website www.altyngold.uk and follow our news on LinkedIn at AltynGold Plc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260329387928/en/

Contact

Further Information:
For further information, please contact:
Hudson Sandler LLP (Public Relations)
Charlie Jack
Kristina Gaysina
+44 (0)207 796 4133
altyngold@hudsonsandler.com

Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations

Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/

Addressing Critical Trade Finance Challenges

The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges.

In many LC transactions, conformity-assessment documents -such as Certificates of Inspection, Certificates of Conformity, or Inspection Reports- are required as part of the documentation package. These documents must be issued prior to export and be verified to ensure LC compliance, which often creates delays and adds operational complexity. The collaboration between Bureau Veritas and Trade Technologies streamlines this process by linking inspection and conformity assessments directly to the trade-finance workflow, enabling faster validation and delivery of the required certificates.

Market Outlook and Growth Potential

The documentary trade sector is forecasted to grow at a 3.1% CAGR through 2029, while receivables finance is projected to expand at 4.2% CAGR during the same period. Documentary trade is expected to remain a core component of the trade finance market well into the 2050s, underscoring the enduring relevance of this collaboration. Current high levels of counterparty and geopolitical uncertainty underscore the value of documentary trade to manage risk in cross-border transactions.

Tangible Benefits for Trade Stakeholders

The collaboration between Trade Technologies and Bureau Veritas promises to deliver meaningful improvements:

• Enhanced Border Efficiency: More streamlined border processes have already contributed to trade cost reductions of up to 5% over the past decade, with ambitious reforms potentially delivering up to 12 percentage points in additional savings.

• Reduced Uncertainty: By combining Trade Technologies’ digital trade expertise with Bureau Veritas’ deep international trade experience, this collaboration is expected to help exporters, importers, and traders reduce uncertainty and improve visibility.

• Compliance Assurance: The collaboration ensures that applicable standards and/or contractual obligations are met before goods move across borders, strengthening compliance with inspection and conformity requirements.

A Practical Alignment

This strategic collaboration reflects a practical alignment between Trade Technologies, industry-leading digital trade processes and Bureau Veritas’ global network of testing, conformity and inspection experts, enabling better coordination of financial, documentary, and regulatory workflows across global trade corridors.

“Our Certificates of Conformity and Inspection have long served as essential gatekeepers in global supply chains, confirming that goods meet applicable standards before they cross borders”, said Stéphanie Peyrot, Government Services Director for Central Southeast Europe. “Through this collaboration with Trade Technologies, we’re now able to integrate these critical documents directly into the trade finance workflow. This means faster processing, greater transparency, and reduced risk for all parties, from exporters and importers to banks and customs authorities. It’s about making compliance work for trade, not against it.”

“Bureau Veritas is an important player for vital documents and data to provide certainty of prompt payment under trade finance instruments”, said Kirk Lundburg, CEO of Trade Technologies. “This collaboration simplifies our communication with Bureau Veritas and reduces the time for delivering key data and documents necessary to get our customers paid for their export transactions. We are delighted to partner with Bureau Veritas to reduce risk and complexity for our shared customers.”

***

About Bureau Veritas:

Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers’ excellence and sustainability, the company innovates to help them navigate change.

Created in 1828, Bureau Veritas’ 82,000 employees deliver services in 140 countries. The company’s technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability.

Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.

For more information, visit http://www.bureauveritas.com, and follow us on LinkedIn.

Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com.

About Trade Technologies:

Trade Technologies is the leading provider of trade finance automation, connectivity, and transaction management services. Established in 1999, the Company has processed almost USD 195 billion in successful trade transactions for thousands of Exporters. Trade Technologies’ innovative solutions, including TradeSharp™ and TradeBridge API, automate and digitize the creation, management, and delivery of documents and data between Corporates, Banks and Buyers. With a global presence in 16 offices across Asia, EMEA and North America, the Company offers a unique blend of technology and expert trade services that optimize transaction processing, enhance cash flow, and provide end-to-end visibility. Clients benefit from faster, more reliable payments and reduced costs.

www.tradetechnologies.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260329411683/en/

Contact

ANALYST/INVESTOR CONTACTS

Laurent Brunelle
+33 (0)1 55 24 76 09
laurent.brunelle@bureauveritas.com

Colin Verbrugghe
+33 (0)1 55 24 77 80
colin.verbrugghe@bureauveritas.com

Romain Gorge
romain.gorge@bureauveritas.com

Inès Lagoutte
ines.lagoutte@bureauveritas.com

MEDIA CONTACTS

Karine Havas
+33 (0)6 68 63 83 18
karine.havas@bureauveritas.com

Frédéric Vallois
+33 (0)6 21 66 31 04
frederic.vallois@bureauveritas.com

Claudia Strasserra
+39 340 3817265
claudia.strasserra@bureauveritas.com

Company Logo

Company Logo

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said.

Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melting pot of ideas and people is driving our long-term growth.”

Premium Orthodontists’ Recommendations Spread in Top Cities

Clear aligner treatment has a long cycle. Subtle differences in product quality and treatment plans accumulate and become impactful over the course of up to a hundred aligners for each case. Premium orthodontists typically require years of personal experience before they embrace a new brand. They are active in high integrity professional communities and often share detailed usage experiences with each other. Their collective views then propel industry adoption trends.

As a result, Angel chose the harder path, that is to go directly to the top cities of the world to provide premium orthodontists with premium local services and clinical support. With the support of our broad global investor base and our talented people, Angel had to make substantial investments and organizational changes to execute this strategy.

After three years of hard work and investment, Angel is proud to say that it has built a strong reputation among premium orthodontists in top cities around the world, especially those who prize clinical excellence. There are hundreds of orthodontists who have each utilized Angel aligner solutions for over a hundred cases, some for over a thousand cases, especially complex cases. Positive word-of-mouth recommendations are spreading from leading orthodontists to the broader orthodontic community. Concurrently, clinicians are gaining a deeper understanding of different clinical outcomes and predictability of different aligner solutions, which is benefiting Angel and other premium brands.

In addition, Angel’s portfolio of many innovations has been welcomed by clinicians around the world. One example is the angelButton™ solution introduced 6 years ago. Angel has shipped more than 100 million angelButtons to customers! What’s more, customer feedback received has been utilized to significantly improve its industrial stability and clinical predictability. The angelButton™ solution is praised for its reliable and mature anchorage function as well as its many proprietary movement protocols that maximize treatment efficiency and comfort. Another example is Angel’s A6 Mandibular Advancement solution, which, thanks to over 10 years of clinical feedback, has achieved excellent clinical efficiency. Angel innovation focuses on solving clinician pain points and improving patient experience, rather than chasing the latest technology topics. More importantly, even innovative technology ideas require long-term clinical feedback and improvement to achieve predictable treatment performance.

Angel collaborates with leading orthodontists to incorporate their insights, thus ensuring a strong pipeline of innovations for years to come. Central to this process is Angel’s open and inclusive culture, which enables the Company to incorporate feedback from internal teams and external customers. Building on this culture, Angel organizes its R&D, clinical support, sales and operational teams in a flexible way to deliver localized solutions in more than 60 countries.

The Company has built specialized education and training, clinical support and experienced sales teams in five major regions — EMEA, North America, APAC, South America and China. It also has established treatment design centers in China, Brazil and Southeast Asia, along with manufacturing facilities in China, the United States and Brazil. The Company will further strengthen its compliance systems, data security processes and intellectual property assets while protecting its innovations.

In 2025, Angel’s global markets（ex-Chinese mainland）recorded 256,200 cases, which increased 82.1%, with revenue of USD 163.0 million, which increased 102.5%. Premium orthodontists’ recommendations and the clinical results they share, especially for complex cases, have propelled the Company into a growth phase driven by professional reputation.

Market Leadership in China by Expanding Product Portfolio and Strong Growth in Lower-Tier Markets

The clear aligner market in China is multi-tiered, with significant differences across regions in practitioner capability, patient profile, and service models.

In China’s first- and second-tier markets, Angel continues to provide comprehensive clinical support for orthodontists to help them produce exemplary clinical outcomes. In 2025, Angel combined traditional orthodontics with digital innovation to introduce solutions for more difficult adult cases, including the Angel Scissors-bite Turbo and Angel Enhanced Curve Turbo. For adolescents and children, Angel introduced solutions that enable more precise intervention during growth stages to make treatment simpler and more comfortable. To improve clinician experience and workflow, the Company delivers biweekly updates for iOrtho, its doctor-facing, ortho-design software.

In China’s broader third- and fourth-tier markets, Angel is fully committed to expanding service coverage and market share. Thanks to systematic training programs, clinical support, and full-cycle solutions, the Company is helping clinicians deliver predictable treatment outcomes, shortened treatment cycles, and reduced case restarts, all of which result in a higher standard of care for a large patient population.

Some aligner brands have exited lower-tier cities and towns. As a result, Angel’s leadership and influence in these regions have been strengthened. Even in lower-tier cities and towns, clinicians are realizing that differences in manufacturing quality, treatment design, and clinical support can accumulate and be magnified, making some cases difficult to finish, and requiring suppliers to continue to ship aligners resulting in prohibitive contingent costs. With this realization, many clinicians in lower-tier cities and towns are turning to higher quality solutions.

In 2025, Angel’s Chinese mainland market reached 276,200 cases, which increased 26.3%, with revenue of USD 207.3 million, which increased 10.1%. Servicing lower-tier markets is not just about business. It’s about ensuring that doctors in hard-to-reach regions receive reliable products and clinical support, and patients get a better standard of aligner therapy.

Angel’s cumulative case volume has exceeded 2 million cases to date. This is a significant milestone because many Angel cases are more complex (simple cases being a different category with different technical barriers to entry). Each Angel case is part of a sophisticated, daily collaboration between many talented people inspired by clinical excellence. This culture, people, organization structure combined with case volume milestone is the foundation for Angel’s sustained growth.

The clear aligner industry has significant development potential. Angel will continue to build on its open and inclusive corporate culture, invest in technical innovations, strengthen its global clinical support systems, and enhance its customer experience. The combination, we believe, will result in sustainable growth worldwide.

About Angelalign Technology Inc.

Founded in 2003 and celebrating 2 million smiles, Angelalign Technology Inc. is a publicly listed company with a broad international shareholder base. It provides digital technology-driven clear aligner products and services in more than 60 countries. Learn more at angelaligner.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260327515887/en/

Contact

Media Contact:
Sue Kolb
sue.kolb@angelaligner.com